Hydroxyurea
Administration
- Type: Antineoplastic
- Dosage Forms:
- Routes of Administration: oral
- Common Trade Names:
Adult Dosing
- Cytoreduction in leukostasis and hyperleukocytosis/hyperviscosity syndrome
- 50 to 100 mg/kg/day
- Sickle cell disease
- 15-35 mg/kg/day
- CML, squamous cell head and neck cancer
- 15mg/kg/day initially
Pediatric Dosing
- Off label for sickle cell, 10-35mg/kg/day
Special Populations
Pregnancy Rating
- D
Lactation risk
- Infant risk cannot be ruledout
Renal Dosing
- Reduce dose if CrCl <60. Administer after dialysis on HD days
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Skin ulceration, skin cancer, gangrene
- Genetic mutations w/longterm use
- Parvovirus infection
Common
- Myelosupression, neutropenia, thrombocytopenia, decreased reticulocyte count
Pharmacology
- Half-life: 2-4.5 hours
- Metabolism: Hepatic 60%
- Excretion: Renal(40%)
Mechanism of Action
- Inhibits DNA synthesis by acting as a ribonucleotide reductase inhibitor